CDSCO bars cosmetic injectables, squeezing India's aesthetic clinic chains
India's drug regulator CDSCO issued a May 18 advisory prohibiting cosmetics from being administered as injections, directly targeting aesthetic clinics offering GLP-1, glutathione, collagen and hyaluronic acid jabs. The move threatens revenue streams for Indian beauty boutiques and aesthetic retail chains that have built service menus around injectable treatments.
India's drug regulator CDSCO issued a May 18 advisory barring cosmetics from being administered as injections, targeting aesthetic clinics offering GLP-1, glutathione, collagen and hyaluronic acid jabs. Move could affect Indian beauty boutiques and aesthetic retail chains.
Why this matters
CDSCO's injectable cosmetics ban extends a wider 2025 enforcement push, following DCGI's nationwide crackdown on illegal sildenafil and tadalafil sales across pharmacies and e-pharmacy platforms.
Retail-brand signals steady at 434 in the last 90 days, with regulatory enforcement a recurring driver.